



State of New Jersey
Department of Human Services
Division of Medical Assistance & Health Services

NEWSLETTER

Volume 28 No. 18

October 2018

TO: Hospitals, Physicians – **For Action**
Health Maintenance Organizations – **For Information Only**

SUBJECT: **NJ FamilyCare (NJFC) Coverage of Long-Acting Reversible Contraceptive (LARC) Devices**

EFFECTIVE: Physician claims with service dates on or after July 1, 2018

PURPOSE: To notify hospitals and physicians of improvements to the NJFC policy regarding coverage of LARC to ensure that NJFC payments cover a physician's acquisition cost for purchasing a LARC product and to improve access to LARC by providing physicians the opportunity to provide this service in an inpatient hospital setting.

BACKGROUND: The NJFC shall provide inpatient hospital coverage for LARC immediate postpartum, defined as within ten (10) minutes after delivery, with a patient's signed consent. This policy removes a restriction limiting access to one of the most effective forms of contraception. Available LARC products currently include Kyleena®, Liletta®, Mirena®, Nexplanon®, ParaGard® and Skyla®

ACTION: Effective for claims with service dates on or after July 1, 2018, NJFC shall provide inpatient hospital coverage for the insertion of a LARC product immediate postpartum following a delivery with a patient's signed consent. In its first phase, physicians will be responsible for providing the LARC product for insertion. A physician would then bill Medicaid/NJFC for both the LARC product and the insertion.

- NJFC fee-for-service allowances for LARC drug acquisition costs shall not exceed the product's Wholesale Acquisition Cost (WAC) less one (1) percent or a physician's charge, whichever is less. Current fee allowances for LARC products are listed in the table below.
- Physicians shall be reimbursed for the insertion or implantation of a LARC product by reporting CPT procedure codes 58300 or 11981, respectively.
- Claims for LARC services provided in an inpatient hospital setting must be submitted on a CMS-1500 health insurance claim form or as an 837P electronic claim transaction.

The Division of Medical Assistance and Health Services is working towards a solution that would provide physicians access to LARC products in the inpatient hospital setting without the need for a physician to purchase or deliver the product to a patient.

LARC Products and Related Billing Information

HCPCS Procedure Code	National Drug Code (NDC)	LARC Product	Current NJFC Fee Allowance
J7296	50419-0424-01	Kyleena® 19.5mg System	\$899.88
J7297	00023-5858-01	Liletta®	\$677.54
J7298	50419-0421-01	Mirena®	\$899.88
J7300	51285-0204-01	ParaGard®	\$800.42
J7301	50419-0422-01	Skyla® 13.5 mg	\$749.30
J7307	00052-4330-01	Nexplanon® 68mg	\$881.40

If you have any questions concerning this Newsletter, please contact Molina Medicaid Provider Services at 1-800-776-6334.

RETAIN THIS NEWSLETTER FOR FUTURE REFERENCE